Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SOPA and SIMPA: normalized single-sample integrated multiomics pathway analysis of tumor heterogeneity in solid cancers.

Briefings in bioinformatics·2026
Same author

Editorial: Honoring Dr. Angelo Azzi's legacy and expanding the horizons of Molecular Aspects of Medicine.

Molecular aspects of medicine·2026
Same author

β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

MicroRNAs in oncology: a translational perspective in the era of AI.

Nature reviews. Clinical oncology·2026
Same author

Transposable Element-Derived miR-28-5p and miR-708-5p: Exploring Potential Roles in Lung Cancer.

Non-coding RNA·2025
Same author

MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy.

Cancer drug resistance (Alhambra, Calif.)·2025

Related Experiment Video

Updated: May 26, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Non-coding RNAs as theranostics in human cancers.

Roxana S Redis1, Ioana Berindan-Neagoe, Victor I Pop

  • 1Department of Molecular Science, University of Medicine and Pharmacy I. Hatieganu, Cluj-Napoca, Romania.

Journal of Cellular Biochemistry
|January 4, 2012
PubMed
Summary
This summary is machine-generated.

Non-coding RNAs (ncRNAs) show promise as theranostics for personalized cancer medicine. This review highlights microRNAs (miRNAs) and future directions for longer ncRNAs in cancer diagnosis and therapy.

Related Experiment Videos

Last Updated: May 26, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Theranostics integrates diagnosis and therapy for personalized medicine.
  • Non-coding RNAs (ncRNAs) play crucial roles in cancer development and progression.
  • MicroRNAs (miRNAs) are extensively studied ncRNAs with significant implications in oncology.

Purpose of the Study:

  • To re-evaluate non-coding RNAs (ncRNAs) as theranostic tools in human cancers.
  • To summarize current therapeutic strategies utilizing microRNAs (miRNAs) in cancer.
  • To explore the future potential of longer ncRNAs in cancer theranostics.

Main Methods:

  • Literature review of ncRNA research in cancer.
  • Analysis of miRNA roles in tumor initiation and progression.
  • Summary of therapeutic approaches targeting miRNAs.

Main Results:

  • MicroRNAs (miRNAs) are confirmed key regulators in all cancer types.
  • ncRNAs, particularly miRNAs, are viable diagnostic and therapeutic targets.
  • Emerging research supports the theranostic potential of longer ncRNAs.

Conclusions:

  • Non-coding RNAs (ncRNAs) represent a promising frontier in cancer theranostics.
  • MicroRNAs (miRNAs) offer established diagnostic and therapeutic applications.
  • Future cancer theranostics will likely leverage longer, more versatile ncRNAs.